eFFECTOR Therapeutics, Inc. (EFTR): Price and Financial Metrics


eFFECTOR Therapeutics, Inc. (EFTR): $1.76

-0.03 (-1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EFTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EFTR Stock Price Chart Interactive Chart >

Price chart for EFTR

EFTR Price/Volume Stats

Current price $1.76 52-week high $40.42
Prev. close $1.79 52-week low $1.65
Day low $1.69 Volume 26,800
Day high $1.85 Avg. volume 31,061
50-day MA $3.56 Dividend yield N/A
200-day MA $8.12 Market Cap 72.85M

eFFECTOR Therapeutics, Inc. (EFTR) Company Bio


eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. The company was incorporated in 2012 and is based in San Diego, California.


EFTR Latest News Stream


Event/Time News Detail
Loading, please wait...

EFTR Latest Social Stream


Loading social stream, please wait...

View Full EFTR Social Stream

Latest EFTR News From Around the Web

Below are the latest news stories about eFFECTOR Therapeutics Inc that investors may wish to consider to help them evaluate EFTR as an investment opportunity.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors. Concurrent with Ms. Harrington-Smith’s appointment, Jonathan Root, M.D., has resigned from the company’s board of direct

Yahoo | February 16, 2022

These 2 Stocks Could Be Bought Out, Says Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion.

Michael Marcus on TipRanks | February 15, 2022

2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth

Yahoo | February 15, 2022

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference. Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will provide an overview of the Company’s clinical developm

Yahoo | February 9, 2022

eFFECTOR Therapeutics provides pipeline update; inks up to $50M investment contract

eFFECTOR Therapeutics (EFTR) announced pipeline updates and an investment agreement with Lincoln Park Capital for a commitment of up to $50M over 36 months.The company said that a

Seeking Alpha | January 24, 2022

Read More 'EFTR' Stories Here

EFTR Price Returns

1-mo N/A
3-mo -63.03%
6-mo -78.14%
1-year -81.93%
3-year N/A
5-year N/A
YTD -78.74%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4291 seconds.